JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on TRVI stock, giving a Buy rating yesterday.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Debanjana Chatterjee’s rating is based on the promising results from Trevi Therapeutics’ Haduvio in its Phase 2a RIVER trial for reducing cough frequency in RCC patients. The data showed significant reductions in daytime cough frequency, which is crucial as coughs are more prevalent during the day. Additionally, the treatment did not exhibit any period effects, and the Leicester Cough Questionnaire scores indicated a substantial improvement, surpassing clinically meaningful thresholds.
Furthermore, the safety profile of Haduvio is considered manageable, with adverse effects decreasing over time. The potential for Haduvio to succeed in its Phase 3 program for IPF-cough and possibly expand its label to RCC with just one trial enhances the development’s capital efficiency. The expert panel highlighted the unmet needs in IPF-cough and RCC, suggesting that Haduvio could become a significant player in these areas due to its efficacy and safety profile.